Summary by Moomoo AI
Ming Kand Pharmaceuticals convened its Board of Directors on 29 April 2024 to consider a motion to amend the registered capital of the Company and amend the Articles of Association. This change is authorized by the General Meeting and involves a number of share changes, including bond transfer requests, enforcement of the Restricted Stock and Stock Futures Incentive Program, share buyback and marketing, and more. After the change in shares, the registered capital of the company decreased from $2,962,088,310 to $2,933,336,997 and the total share capital changed from 2,962,088,310 shares to 2,933,336,997 shares. The relevant terms of the Articles of Association will also be amended to reflect the above changes.